Associations between epigenetic aging with cognitive aging and neuropsychiatric measures are not well-understood.
Objective:
1) To assess cross-sectional correlations between second-generation DNA methylation (DNAm)-based clocks of healthspan and lifespan (i.e., GrimAge, PhenoAge, and DNAm-based estimator of telomere length [DNAmTL]) and cognitive and neuropsychiatric measures; 2) To examine longitudinal associations between change in DNAm markers and change in cognition over 2 years.
Methods:
Participants were members of VITAL-DEP (VITamin D and OmegA-3 TriaL- Depression Endpoint Prevention) study. From previously ascertained cognitive groups (i.e., cognitively normal and mild cognitive impairment), we randomly selected 45 participants, aged≥60 years, who completed in-person neuropsychiatric assessments at baseline and 2 years. The primary outcome was global cognitive score (averaging z-scores of 9 tests). Neuropsychiatric Inventory severity scores were mapped from neuropsychiatric symptoms (NPS) from psychological scales and structured diagnostic interviews. DNAm was assayed using Illumina MethylationEPIC 850K BeadChip at baseline and 2 years. We calculated baseline partial Spearman correlations between DNAm markers and cognitive and NPS measures. We constructed multivariable linear regression models to examine longitudinal relations between DNAm markers and cognition.
Results:
At baseline, we observed a suggestive negative correlation between GrimAge clock markers and global cognition but no signal between DNAm markers and NPS measures. Over 2 years: each 1-year increase in DNAmGrimAge was significantly associated with faster declines in global cognition; each 100-base pair increase in DNAmTL was significantly associated with better global cognition.
Conclusion:
We found preliminary evidence of cross-sectional and longitudinal associations between DNAm markers and global cognition.
HickmanRA, FaustinA, WisniewskiT (2016) Alzheimer disease and its growing epidemic: Risk factors, biomarkers, and the urgent need for therapeutics. Neurol Clin34, 941–953.
2.
SalamehY, BejaouiY, ElHajj N (2020) DNA methylation biomarkers in aging and age-related diseases. Front Genet11, 171.
3.
PagiatakisC, MusolinoE, GornatiR, BernardiniG, PapaitR (2021) Epigenetics of aging and disease: A brief overview. Aging Clin Exp Res33, 737–745.
4.
LevineME, LuAT, QuachA, ChenBH, AssimesTL, BandinelliS, HouL, BaccarelliAA, StewartJD, LiY, WhitselEA, WilsonJG, ReinerAP, AvivA, LohmanK, LiuY, FerrucciL, HorvathS (2018) An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY)10, 573–591.
BergsmaT, RogaevaE (2020) DNA methylation clocks and their predictive capacity for aging phenotypes and healthspan. Neurosci Insights15, 2633105520942221.
8.
HillaryRF, StevensonAJ, CoxSR, McCartneyDL, HarrisSE, SeebothA, HighamJ, SproulD, TaylorAM, RedmondP, CorleyJ, PattieA, HernándezM, Muñoz-ManiegaS, BastinME, WardlawJM, HorvathS, RitchieCW, Spires-JonesTL, McIntoshAM, EvansKL, DearyIJ, MarioniRE (2021) An epigenetic predictor of death capturesmulti-modal measures of brain health. Mol Psychiatry26, 3806–3816.
9.
MarioniRE, ShahS, McRaeAF, RitchieSJ, Muniz-TerreraG, HarrisSE, GibsonJ, RedmondP, CoxSR, PattieA, CorleyJ, TaylorA, MurphyL, StarrJM, HorvathS, VisscherPM, WrayNR, DearyIJ (2015) The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. Int J Epidemiol44, 1388–1396.
10.
O’SheaDM, AlaimoH, DavisJD, GalvinJE, TremontG (2023) A comparison of cognitive performances based on differing rates of DNA methylation GrimAge acceleration among older men and women. Neurobiol Aging123, 83–91.
11.
ReedRG, CarrollJE, MarslandAL, ManuckSB (2022) DNA methylation-based measures of biological aging and cognitive decline over 16-years: Preliminary longitudinal findings in midlife. Aging (Albany NY)14, 9423–9444.
12.
SugdenK, CaspiA, ElliottML, BourassaKJ, ChamartiK, CorcoranDL, HaririAR, HoutsRM, KothariM, KritchevskyS, KuchelGA, MillJS, WilliamsBS, BelskyDW, MoffittTE (2022) Association of pace of aging measured by blood-based DNA methylation with age-related cognitive impairment and dementia. Neurology99, e1402–e1413.
13.
VaccarinoV, HuangM, WangZ, HuiQ, ShahAJ, GoldbergJ, SmithN, KaseerB, MurrahN, LevantsevychOM, ShallenbergerL, DriggersE, BremnerJD, SunYV (2021) Epigenetic age acceleration and cognitive decline: A twin study. J Gerontol A Biol Sci Med Sci76, 1854–1863.
14.
WadsworthLP, LoriusN, DonovanNJ, LocascioJJ, RentzDM, JohnsonKA, SperlingRA, MarshallGA (2012) Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord34, 96–111.
OkerekeOI, PrescottJ, WongJY, HanJ, RexrodeKM, De VivoI (2012) High phobic anxiety is related to lower leukocyte telomere length inwomen. PLoS One7, e40516.
17.
SimonNM, SmollerJW, McNamaraKL, MaserRS, ZaltaAK, PollackMH, NierenbergAA, FavaM, WongKK (2006) Telomere shortening and mood disorders: Preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry60, 432–435.
18.
OkerekeOI, ReynoldsCF3rd, MischoulonD, ChangG, CookNR, CopelandT, FriedenbergG, BuringJE, MansonJE (2018) The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. Contemp Clin Trials68, 133–145.
19.
MansonJE, BassukSS, LeeIM, CookNR, AlbertMA, GordonD, ZaharrisE, MacfadyenJG, DanielsonE, LinJ, ZhangSM, BuringJE (2012) TheVITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a largerandomized controlled trial of vitamin D and marine omega-3 fattyacid supplements for the primary prevention of cancer andcardiovascular disease. Contemp Clin Trials33, 159–171.
BeeklyDL, RamosEM, van BelleG, DeitrichW, ClarkAD, JackaME, KukullWA (2004) The National Alzheimer’s Coordinating Center (NACC) Database: An Alzheimer disease database. Alzheimer Dis Assoc Disord18, 270–277.
22.
WeintraubS, SalmonD, MercaldoN, FerrisS, Graff-RadfordNR, ChuiH, CummingsJ, DeCarliC, FosterNL, GalaskoD, PeskindE, DietrichW, BeeklyDL, KukullWA, MorrisJC (2009) The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): The neuropsychologic test battery. Alzheimer Dis Assoc Disord23, 91–101.
23.
DickersonBC, SperlingRA, HymanBT, AlbertMS, BlackerD (2007) Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry64, 1443–1450.
24.
OkerekeOI, CopelandM, HymanBT, WanggaardT, AlbertMS, BlackerD (2011) The Structured Interview & Scoring Tool-Massachusetts Alzheimer’s Disease Research Center (SIST-M): Development, reliability, and cross-sectional validation of a brief structured clinical dementia rating interview. Arch Neurol68, 343–350.
25.
KangJH, VyasCM, OkerekeOI, OgataS, AlbertM, LeeIM, D’AgostinoD, BuringJE, CookNR, GrodsteinF, MansonJE (2022) Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. Alzheimers Dement (N Y)8, e12288.
26.
TengEL, ChuiHC (1987) The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry48, 314–318.
27.
AlbertM, SmithLA, ScherrPA, TaylorJO, EvansDA, FunkensteinHH (1991) Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci57, 167–178.
28.
BrandtJ, SpencerM, FolsteinM (1988) The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol1, 111–117.
29.
RoyallDR, LauterbachEC, CummingsJL, ReeveA, RummansTA, KauferDI, LaFranceWCJr., CoffeyCE (2002) Executive control function: A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci14, 377–405.
30.
ReitanR (1992) Trail Making Test. Manual for administrationand scoring. Reitan Neuropsychological Laboratory, Tucson, AZ.
31.
KroenkeK, SpitzerRL, WilliamsJB (2001) The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med16, 606–613.
32.
SpitzerRL, KroenkeK, WilliamsJB, LöweB (2006) A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med166, 1092–1097.
33.
SheehanDV, LecrubierY, SheehanKH, AmorimP, JanavsJ, WeillerE, HerguetaT, BakerR, DunbarGC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry59Suppl 20, 22–33;quiz 34–57.
34.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
35.
VyasCM, HazraA, ChangSC, QiuW, ReynoldsCF3rd, MischoulonD, ChangG, MansonJE, De VivoI, OkerekeOI (2019) Pilot study of DNA methylation, molecular aging markers and measures of health and well-being in aging. Transl Psychiatry9, 118.
36.
AryeeMJ, JaffeAE, Corrada-BravoH, Ladd-AcostaC, FeinbergAP, HansenKD, IrizarryRA (2014) Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics30, 1363–1369.
37.
FortinJP, TricheTJJr., HansenKD (2017) Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. Bioinformatics33, 558–560.
38.
HorvathS (2013) DNA methylation age of human tissues and cell types. Genome Biol14, R115.
39.
HorvathS, LevineAJ (2015) HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis212, 1563–1573.
40.
HousemanEA, AccomandoWP, KoestlerDC, ChristensenBC, MarsitCJ, NelsonHH, WienckeJK, KelseyKT (2012) DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics13, 86.
41.
CharlsonME, PompeiP, AlesKL, MacKenzieCR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis40, 373–383.
42.
DeyoRA, CherkinDC, CiolMA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol45, 613–619.
43.
Huangda W, ShermanBT, LempickiRA (2009) Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res37, 1–13.
44.
FransquetPD, LacazeP, SafferyR, ShahRC, VryerR, MurrayA, WoodsRL, RyanJ (2021) Accelerated epigenetic aging in peripheral blood does not predict dementia risk. Curr Alzheimer Res18, 443–451.
45.
ShadyabAH, McEvoyLK, HorvathS, WhitselEA, RappSR, EspelandMA, ResnickSM, MansonJE, ChenJC, ChenBH, LiW, HaydenKM, BaoW, KustersCDJ, LaCroixAZ (2022) Association of epigenetic age acceleration with incident mild cognitive impairment and dementia among older women. J Gerontol A Biol Sci Med Sci77, 1239–1244.
46.
SibbettRA, AltschulDM, MarioniRE, DearyIJ, StarrJM, RussTC (2020) DNA methylation-based measures of accelerated biological ageing and the risk of dementia in the oldest-old: A study of the Lothian Birth Cohort 1921. BMC Psychiatry20, 91.
47.
DoganF, ForsythNR (2021) Telomerase regulation: A role forepigenetics. Cancers (Basel)13, 1213.
